Response to: a true point-of-care molecular testing method for tailored therapy for Helicobacter pylori eradication

"Response to: a true point-of-care molecular testing method for tailored therapy for Helicobacter pylori eradication." Expert Review of Gastroenterology & Hepatology, 17(3), p. 311

Declaration of interest

DY Graham is a consultant for RedHill Biopharma and Phathom Pharmaceuticals regarding novel Helicobacter pylori therapies. He has received research support for culture of H. pylori and is the principal investigator of an international study of the use of anti-mycobacterial therapy for Crohn’s disease. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Author contributions

Both authors were responsible for the concept and writing of the manuscript.

Additional information

Funding

DY Graham is supported in part by the Office of Research and Development Medical Research Service Department of Veterans Affairs, Public Health Service grant DK56338, which funds the Texas Medical Center Digestive Diseases Center.